Families of Spinal Muscular Atrophy Announces $700,000 Funding for Novel Drug Program at Newly Created California Institute for Biomedical Research

Post date: May 17, 2013 2:46:39 PM

May 10, 2012

Families of Spinal Muscular Atrophy Announces $700,000 Funding for Novel Drug Program at Newly Created California Institute for Biomedical Research

This new program will focus on optimizing small molecule drug candidates which increase the SMA back-up gene in order to make them ready for human clinical trials. It is well demonstrated that increasing production from the back-up gene can lead to improvement in mouse models of SMA. Small molecule drug candidates have particular advantages: mainly ease of use by oral dosing and the ability to clear the drug quickly from the body. Dr. Peter Schultz, a renowned chemist and successful biotech leader, will be leading this new research effort.

In addition to founding the California Institute for Biomedical Research where the Families of SMA funded project will take place. Dr. Schultz also was Institute Director at the Genomics Institute of the Novartis Research Foundation (GNF) from 1999 to 2010. Dr. Schultz has founded multiple biotech companies, including Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Technologies, Ilypsa, Ambrx and Wildcat Technologies. Dr. Schultz has published over 500 scientific publications, and received numerous awards for his work including: the Waterman Award of the National Science Foundation, the 1994 Wolf Prize in Chemistry, the 2003 Paul Ehrlich Prize, and the 2005 Arthur C. Cope Award of the American Chemical Society. He is a member of the National Academy of Sciences and the Institute of Medicine.

Click here to read full article